Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate
Caramelli, Bruno; Bernoche, Claudia Y. S. M. de; Sartori, Ana M. C; Sposito, Andrei C; Santos, Raul D; Monachini, Maristela C; Strabelli, Tania; Uip, Davi.
Braz. j. infect. dis
; 5(6): 332-338, dec. 2001.
Artigo
em Inglês
| LILACS | ID: lil-331042
Hyperlipidemia has been frequently recorded as a side effect of treating HIV patients with protease inhibitors (PI). This study was initiated to analyze the modifications on blood lipids in HIV-patients receiving PI and the safety and efficacy of the treatment with fenofibrate. Total (TC) and HDL-cholesterol, triglycerides (TG), and CD(4)(+) T-cell counts were measured in 30 HAART-naive patients (Group I) before and after PI introduction. In a second phase of the study, the effects of fenofibrate on lipids, CPK, CD(4)(+), and viral load were determined in 13 patients (Group II) with elevated TC or TG. In Group I, 60 of the patients showed TC or TG elevations. Average increments of 31 and 146 in TC and TG respectively (p<0.0006 and p<0.0001) were observed. In Group II, fenofibrate treatment was associated with decrements of 6.6 (TC) and 45.7 (TG) (p=0.07 and 0.0002) and no modifications on CPK, CD(4)(+), and viral load. In conclusion, hyperlipidemia is common during the treatment of HIV with protease inhibitors, and fenofibrate appears to be an effective and safe choice for its treatment.
Biblioteca responsável:
BR1.1
Texto completo
Documentos relacionados